Phase III Randomized Study of Postradiotherapy Chemotherapy with Combination α-Difluoromethylornithine-PCV versus PCV for Anaplastic Gliomas

Purpose: In the current study, we sought to determine whether the addition of DFMO (α-difluoromethyl ornithine; eflornithine), an inhibitor of ornithine decarboxylase, to a nitrosourea-based therapy procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, vincristine (PCV) would be more effective...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2003-03, Vol.9 (3), p.981-990
Hauptverfasser:	LEVIN, Victor A, HESS, Kenneth R, GLEASON, Mary Jo, KIM, Hyung-Woo, CHOUCAIR, Ali, FLYNN, Patrick J, JAECKLE, Kurt A, KYRITSIS, Athanassios P, YUNG, W. K, PRADOS, Michael D, BRUNER, Janet M, ICTECH, Sandra
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Astrocytoma - drug therapy Astrocytoma - mortality Biological and medical sciences Brain Neoplasms - drug therapy Brain Neoplasms - mortality Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Disease-Free Survival Eflornithine - administration & dosage Female Glioma - drug therapy Glioma - mortality Humans Male Medical sciences Middle Aged Oligodendroglioma - drug therapy Oligodendroglioma - mortality Pharmacology. Drug treatments Time Factors Vincristine - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!